S. Lasserre

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

J. Blay, M. Hidalgo, J. Baselga, 2015, The New England journal of medicine.

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.

T. Gruenberger, J. Bridgewater, M. Rivoire, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab Safety in Patients with Central Nervous System Metastases

B. Besse, U. Rohr, S. Lasserre, 2009, Clinical Cancer Research.

Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

F. Bosch, R. Foà, S. Stilgenbauer, 2014 .

Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

J. Blay, J. Baselga, J. Tabernero, 2015 .

Safety of bevacizumab in patients with metastases to the central nervous system.

S. Lasserre, P. Compton, S. Augustus, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1816 Preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

A. Schneeweiss, D. Miles, F. Puglisi, 2015 .